The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
15633995 |
66 |
Control of hepatitis C: a medicinal chemistry perspective.![EBI](/images/logo_chembl.png) |
University of Wollongong |
15801859 |
40 |
Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors.![EBI](/images/logo_chembl.png) |
Imim/Universitat Pompeu Fabra |
15080998 |
21 |
Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease.![EBI](/images/logo_chembl.png) |
Irbm, Mrl Rome |
14741292 |
18 |
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.![EBI](/images/logo_chembl.png) |
Shire Biochem |
14741291 |
19 |
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.![EBI](/images/logo_chembl.png) |
Shire Biochem |
12951122 |
20 |
Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase.![EBI](/images/logo_chembl.png) |
Shire Biochem |
12643923 |
22 |
Glycine alpha-ketoamides as HCV NS3 protease inhibitors.![EBI](/images/logo_chembl.png) |
Pharmaceutical Research Institute |
11844706 |
30 |
Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.![EBI](/images/logo_chembl.png) |
Irbm, Mrl Rome |
24022489 |
18 |
Structural basis of mycobacterial inhibition by cyclomarin A![BDB](/images/logo_bindingdb.png) |
Novartis Institute For Tropical Diseases |
23955344 |
9 |
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.![BDB](/images/logo_bindingdb.png) |
University of Michigan Medical School |
11861807 |
8 |
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.![BDB](/images/logo_bindingdb.png) |
Istituto Di Chimica Biomolecolare |
17973363 |
13 |
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).![BDB](/images/logo_bindingdb.png) |
Bristol-Myers Squibb Pharmaceutical Research Institute |
14561086 |
14 |
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.![BDB](/images/logo_bindingdb.png) |
Boehringer Ingelheim Pharmaceuticals |